The Zhitong Finance App learned that Daiwa released a research report stating that the minimally invasive robot (02252) was given a “buy” rating for the first time, with a target price of HK$47. Currently, the penetration rate of China's surgical robotics industry is low, and it is dominated by international companies. According to forecasts, the market's compound annual growth rate for 2021-26 will be 38.4%. The bank believes that with a comprehensive product portfolio and favorable policies, the company can maintain its leading position in the country.

According to the report, the group's three flagship products, including Tumay, Dragonfly Eye, and Hug, have all been approved by China's National Drug Administration, and the bank expects the three products to start generating revenue in the near future. In terms of catalysts, including an increase in the average income of Tumay, Dragonfly Eye, and Kuke during the 2022-23 period, the approval of more indications in 2022-23, and an increase in hospital penetration rates.